Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
216.17 K
Value Traded
10.93 M
Short % Float
2.67%
Days to Cover
2.5
-8.58%Week
-16.42%1 Month
-23.56%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
924.88 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
904.87 M
Total Shares
66.30 M
Float Shares
29.47 M
Insiders
55.55%
Institutions
14.78%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
LTGO Catalyst Timeline
Dated clinical, regulatory and corporate events for Latigo Biotherapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Latigo Biotherapeutics, Inc.
11Total events
4Upcoming
2Tier-1 (high impact)
2026 to 2029Coverage
Upcoming catalysts 2
Past FDA Catalysts and PDUFA Decisions
How LTGO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every LTGO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Foresite Capital Management V, LLC10% Owner | Buy | 140,000 2,008,024 held | $18.00 | 08/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LTGO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LTGO for Q2 2026. | ||||
LTGO Institutional Ownership Trends
LTGO Short Interest
Shares sold short, counted twice a month.
2.67%
Short % of Float
of tradable shares sold short
785.9K
Shares Sold Short
-5.6% vs prior count
2.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
314.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LTGO ranks across every disease it competes in
Competitive Position is a premium feature
See how LTGO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLTGO News
-LTGO
Sep 3, 2026Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Latigo Biotherapeutics reported strong financial results for Q2 2026, highlighted by a successful IPO that raised $397.4 million. The company published positive clinical trial results for its pain medication onzotrigine in the New England Journal of Medicine. Additionally, Latigo expanded its leadership team with the appointment of Dr. Naomi Lowy, enhancing its regulatory affairs capabilities.
Read more →-LTGO
Aug 7, 2026Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering
Latigo Biotherapeutics has announced the pricing of its upsized initial public offering, offering 19.2 million shares at $18.00 each, aiming to raise $345.6 million. The shares will begin trading on Nasdaq under the ticker LTGO on August 7, 2026, with the offering expected to close on August 10, 2026. Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities are managing the offering.
Read more →-LTGO
Jul 29, 2026Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain
Latigo Biotherapeutics has published positive results from its LTG-001 abdominoplasty clinical trial in the New England Journal of Medicine. The study demonstrated significant pain reduction and rapid analgesia in patients with moderate-to-severe postoperative pain. LTG-001, a selective Nav1.8 inhibitor, showed a greater analgesic effect than the opioid comparator, Vicodin, and has potential opioid-sparing benefits.
Read more →-LTGO
Jul 8, 2026Latigo Biotherapeutics Appoints Todd Smith to its Board of Directors
Latigo Biotherapeutics has appointed Todd Smith to its board of directors. Smith, CEO of Corium, brings over three decades of experience in the biopharmaceutical industry, particularly in commercialization and product launches. His addition is seen as a strategic move to enhance Latigo's mission of developing innovative non-opioid pain therapies.
Read more →-LTGO
Apr 8, 2026Latigo Biotherapeutics Appoints Sara M. Bonstein to its Board of Directors and as Audit Committee Chair
Latigo Biotherapeutics has appointed Sara M. Bonstein to its board of directors and as chair of the audit committee. Bonstein, currently CFO of Insmed, brings over 20 years of financial leadership experience in biotechnology. Her expertise is expected to support Latigo's growth and advancement of its non-opioid pain management pipeline.
Read more →-LTGO
Mar 3, 2026Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer and Chief Business Officer
Latigo Biotherapeutics has appointed Neha Krishnamohan as Chief Financial Officer and Chief Business Officer. With over 15 years of experience in healthcare investment banking and corporate finance, she is expected to play a crucial role in advancing Latigo's non-opioid pain pipeline. The company aims to address the opioid addiction crisis while improving pain management outcomes.
Read more →-LTGO
Mar 17, 2025Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics
Latigo Biotherapeutics has successfully closed a $150 million Series B financing round to advance its non-opioid pain therapeutics, particularly focusing on its Na v 1.8 inhibitors. The funding, led by Blue Owl Capital, will support the development of Latigo's pipeline and its mission to provide safer pain management alternatives. The company recently reported positive Phase 1 results for its lead candidate, LTG-001.
Read more →-LTGO
Mar 3, 2025Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Nav1.8 Inhibitor for the Non-Opioid Treatment of Acute Pain
Latigo Biotherapeutics has received FDA Fast Track designation for LTG-001, an investigational Na v 1.8 inhibitor aimed at treating acute pain. This designation will expedite its development and regulatory review process. The Phase 1 trial results indicated a favorable safety profile and rapid absorption, suggesting potential for effective pain relief without opioid risks.
Read more →-LTGO
Nov 19, 2024Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair
Latigo Biotherapeutics has appointed Timothy P. Walbert as the new chair of its board of directors. Walbert, who has extensive experience in the biopharmaceutical industry, previously led Horizon Therapeutics through its acquisition by Amgen. His appointment is expected to enhance Latigo's focus on developing non-opioid pain therapies.
Read more →-LTGO
Oct 16, 2024Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical Trial of LTG-305 for Non-Opioid Treatment of Pain
Latigo Biotherapeutics has initiated a Phase 1 clinical trial for LTG-305, a non-opioid treatment for chronic pain. The trial will assess the safety, tolerability, and pharmacokinetics of LTG-305 in healthy volunteers. Results are expected in mid-2025, and the drug targets pain mechanisms with a focus on avoiding central nervous system side effects.
Read more →About Latigo Biotherapeutics, Inc.
Headquarters1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS, CA
BIOPHARMAWATCH ELITE PLUS
Trade the next LTGO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime